The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice.

Ariano, R., Berto, P., Incorvaia, C., Di Cara, G., Boccardo, R., La Grutta, S., et al. (2009). Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 103(3), 254-259 [10.1016/S1081-1206(10)60190-1].

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma

LA GRUTTA, Stefania;
2009-01-01

Abstract

The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice.
2009
Ariano, R., Berto, P., Incorvaia, C., Di Cara, G., Boccardo, R., La Grutta, S., et al. (2009). Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 103(3), 254-259 [10.1016/S1081-1206(10)60190-1].
File in questo prodotto:
File Dimensione Formato  
(34) Ariano_Annals2009_Economic evaluation of sublingual.pdf

accesso aperto

Dimensione 167.1 kB
Formato Adobe PDF
167.1 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/102879
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 25
social impact